News
CRVS
1.400
-0.71%
-0.010
Weekly Report: what happened at CRVS last week (0415-0419)?
Weekly Report · 21h ago
Weekly Report: what happened at CRVS last week (0408-0412)?
Weekly Report · 04/15 10:59
12 Health Care Stocks Moving In Tuesday's After-Market Session
Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. ATyr Pharma shares rose 10.45% and Corvus Pharma shares increased by 7.36%. Apyx Medical shares declined by 6.1% during the session.
Benzinga · 04/09 20:31
Corvus Pharmaceuticals Announces Initiation Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis
Benzinga · 04/09 20:02
CORVUS PHARMACEUTICALS INC: TRIAL IS EXPECTED TO ENROLL 64 PATIENTS AT 12 SITES IN UNITED STATES
Reuters · 04/09 20:01
Weekly Report: what happened at CRVS last week (0401-0405)?
Weekly Report · 04/08 11:04
Cantor Fitzgerald Reiterates Overweight on Corvus Pharma
Benzinga · 04/01 15:16
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
NASDAQ · 04/01 13:35
Weekly Report: what happened at CRVS last week (0325-0329)?
Weekly Report · 04/01 11:02
Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns
TipRanks · 03/29 08:25
Corvus Pharmaceuticals Is Maintained at Neutral by Mizuho
Dow Jones · 03/27 17:32
Corvus Pharmaceuticals Price Target Maintained With a $3.50/Share by Mizuho
Dow Jones · 03/27 17:32
Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target
Benzinga · 03/27 17:21
Weekly Report: what happened at CRVS last week (0318-0322)?
Weekly Report · 03/25 11:05
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 03/22 16:00
Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns
TipRanks · 03/21 06:01
Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/20 11:24
Corvus Pharmaceuticals Price Target Cut to $7.00/Share From $8.00 by Oppenheimer
Dow Jones · 03/20 11:24
Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7
Benzinga · 03/20 11:14
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q4 2023
Corvus Pharma reported earnings per share of -14 cents. This was below the analyst estimate for EPS of -12 cents. The company did not report any revenue for the quarter. The stock was down 2.7% to $3.05 in afternoon trading.
Investorplace · 03/20 00:53
More
Webull provides a variety of real-time CRVS stock news. You can receive the latest news about Corvus Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.